Preparation, characterization, and comparison of the release of antibacterial peptide CM۱۱ from PLGA nanoparticles and microparticles

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 20

فایل این مقاله در 11 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-29-11_003

تاریخ نمایه سازی: 22 آبان 1405

چکیده مقاله:

Objective(s): Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacterium capable of causing acute and chronic infections. Treating these infections is increasingly challenging as this bacterium develops antibiotic resistance. Antimicrobial peptides (AMPs) have emerged as promising therapeutic candidates due to their broad-spectrum activity. Cecropin-Melittin-۱۱ (CM۱۱), a cationic AMP, has shown antimicrobial activity against various pathogens. However, the progression of AMPs from preclinical research to clinical application is hindered by enzymatic degradation, short systemic half-life, and cytotoxicity. To overcome these challenges, poly(lactic-co-glycolic acid)(PLGA) particles for peptide delivery have gained attention.Materials and Methods: CM۱۱-loaded PLGA nanoparticles (NPCM۱۱) and microparticles (MPCM۱۱) were prepared using a double-emulsion solvent evaporation (W۱/O/W۲) method and characterized for particle size, morphology, encapsulation efficiency, and in vitro release. Their antibacterial activity against planktonic and biofilm-forming P. aeruginosa was evaluated using broth microdilution assay. Their cytocompatibility was evaluated using ۳-(۴,۵-Dimethylthiazol-۲-yl)-۲,۵-Diphenyltetrazolium Bromide (MTT) assay.Results: Optimum formulations of NPCM۱۱ and MPCM۱۱ were synthesized, exhibiting spherical morphology with average sizes of ۲۸۱ nm and ۷.۶۳ µm, respectively. The encapsulation efficiency (EE%) of NPCM۱۱ and MPCM۱۱ was ۶۳.۵% and ۶۰.۳%, respectively, while the in vitro CM۱۱ release was ۸۲% and ۵۸%. According to broth microdilution and biofilm inhibition assays, NPCM۱۱ outperformed free CM۱۱ and MPCM۱۱ against planktonic bacteria, whereas both NPCM۱۱ and MPCM۱۱ were superior to free CM۱۱ in biofilm inhibition. MTT assay revealed that NPCM۱۱ and MPCM۱۱ significantly reduced CM۱۱ cytotoxicity. Conclusion: Overall, NPCM۱۱ and MPCM۱۱ were promising formulations of CM۱۱ for treating P. aeruginosa infections.

نویسندگان

- -

Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

- -

Tissue Engineering and Regenerative Medicine Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

- -

Department of Biophysics, College of Biological Sciences, Tarbiat Modares University, Tehran, Iran

- -

Health Management Research Center, Lifestyle and Spiritual Health Research Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

- -

Trauma Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

- -

Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, ...
  • Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. ...
  • Huan Y, Kong Q, Mou H, Yi hr. Antimicrobial peptides: ...
  • Zhang QY, Yan ZB, Meng YM, Hong XY, Shao G, ...
  • Xuan J, Feng W, Wang J, Wang R, Zhang B, ...
  • Ali M, Garg A, Srivastava A, Arora PK. The role ...
  • Amani J, A. Barjini K, M. Moghaddam M, Asadi A. ...
  • Moosazadeh Moghaddam M, Abolhassani F, Babavalian H, Mirnejad R, Azizi ...
  • Heiat M, Aghamollaei H, Moghaddam MM, Kooshki hr. Using CM۱۱ ...
  • Cheng Y, Qin J, Huang Y, Wang T. The antimicrobial ...
  • Jiao X, Dong X, Shan H, Qin Z. Assessing the ...
  • Carnero Canales CS, Roque‐Borda CA, Cazorla JI, Cazorla RM, Apaza ...
  • Khademi F, Sahebkar A, Fasihi‐Ramandi M, Taheri RA. Induction of ...
  • Eshaghi M, Dehghani M, Abedi A, Moosazadeh Moghaddam M, Taheri ...
  • Nkansah MK, Tzeng SY, Holdt AM, Lavik EB. Poly (lactic‐co‐glycolic ...
  • Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, ...
  • Chen W, Hu S. Suitable carriers for encapsulation and distribution ...
  • Wu H, Moser C, Wang HZ, Høiby N, Song ZJ. ...
  • Furukawa S, Kuchma SL, O’toole GA. Keeping their options open: ...
  • McCall RL, Sirianni RW. PLGA nanoparticles formed by single-or double-emulsion ...
  • Oyaghire SN, Quijano E, Piotrowski-Daspit AS, Saltzman WM, Glazer PM. ...
  • Haque S, Boyd BJ, McIntosh MP, Pouton CW, Kaminskas LM, ...
  • Kızılbey K. Optimization of rutin-loaded PLGA nanoparticles synthesized by single-emulsion ...
  • Filippov SK, Khusnutdinov R, Murmiliuk A, Inam W, Zakharova LY, ...
  • CLSI C. Performance standards for antimicrobial susceptibility testing. Clinical Lab ...
  • Haney EF, Trimble MJ, Hancock RE. Microtiter plate assays to ...
  • Singh R, Kesharwani P, Mehra NK, Singh S, Banerjee S, ...
  • Saucedo-Balderas MM, Delgado-Alfaro RA, MartínezMartínez FJ, Ortegón-Reyna D, Bernabé-Pineda M, ...
  • Aboul-eneın Y, Bunacıu A, Fleschın S. Evaluation of the protein ...
  • Dos Santos AP, Oliveira RC, Louchard BO, Uchoa AF, Ricardo ...
  • Ali M, van Gent ME, de Waal AM, van Doodewaerd ...
  • Wang L, Hu C, Shao L. The antimicrobial activity of ...
  • Cresti L, Conte G, Cappello G, Brunetti J, Falciani C, ...
  • نمایش کامل مراجع